Genmab announces Phase III study of Arzerra® met primary endpoint in patients with relapsed CLL

Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p=0.0036) compared to those given fludarabine and cyclophosphamide alone. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Drug development Therapeutic drug monitoring Legislation & regulation Oncology Patient care Research arzerra COMPLEMENT 2 study cyclophosphamide fludarabi Source Type: news